A Prospective, Randomized Trial Comparing Low-dose Rosuvastatin Plus Ezetimibe Versus High-dose Rosuvastatin in Acute Myocardial Infarction Patients Undergoing Percutaneous Coronary Intervention

What this Trial Is About

This research aims to evaluate whether using a combination of low dose rosuvastatin (5 mg) and ezetimibe (10 mg) is not less effective than using a higher dose of rosuvastatin (20 mg) alone in reducing major adverse cardiac events for patients with acute myocardial infarction treated with percutaneous coronary intervention. Previous studies have shown the importance of lowering LDL cholesterol in reducing heart disease risk, but the combined treatment's clinical effectiveness needs further study. Participants will be randomly assigned to receive either rosuvastatin 5 mg plus ezetimibe 10 mg once daily or rosuvastatin 20 mg once daily for 24 months. This open-label trial compares the two regimens over two years to assess their impact on heart-related outcomes. The trial is led by Kiyuk Chang, MD, PhD. During the study, participants will be monitored for major adverse cardiovascular events over 24 months, including death, heart attacks, strokes, and need for revascularization. Additional assessments include LDL cholesterol levels at 3 months, medication adherence, muscle symptoms, new diabetes onset, and cataract occurrence. Safety and effectiveness data will be collected regularly to understand the treatments' impact over the two-year period.

Low Dose Rosuvastatin Plus Ezetimibe Versus High-dose Rosuvastatin in AMI